NCT07470489 2026-04-16
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07521670 2026-04-13
STRAP
National Cancer Centre, Singapore
Phase 2 Not yet recruiting
NCT07337447 2026-01-13
REWENEC 01
Hospices Civils de Lyon
Phase 2 Not yet recruiting
NCT07156019 2025-09-04
Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07024277 2025-06-17
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Not yet recruiting
NCT06951243 2025-04-30
A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer
Beijing GoBroad Hospital
Phase 2 Not yet recruiting
NCT06429397 2025-04-29
Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06816394 2025-02-10
TAURUS
National Taiwan University Hospital
Phase 2 Not yet recruiting
NCT06764368 2025-01-08
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
Beijing Chest Hospital
Phase 2 Not yet recruiting
NCT04889742 2023-12-26
HETERERO
Charite University, Berlin, Germany
Phase 2 Not yet recruiting
NCT05894486 2023-06-08
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Peking University
Phase 2 Not yet recruiting